Your search found 1 Results
CONTRACEPTIVE TECHNOLOGY UPDATE. 1995 Jan; 16(1):11-4.In the US, the Native American Women's Health Education Resources Center, the Latina Roundtable on Health and Reproductive Rights, the National Women's Health Network (NWHN), and the National Black Women's Health Project joined together to request that the US Food and Drug Administration (FDA) impose a moratorium on the use of the contraceptive injectable Depo-Provera. These consumer advocates maintain that Depo-Provera has never been proved to be safe. These same groups issued early warnings about potential problems with the removal of the Norplant, and their efforts led to new patient information inserts for Norplant which include reports of adverse reactions to the implants which were not revealed by clinical studies. The consumer groups agree that Depo-Provera is an effective contraceptive but express serious reservations about its potential side effects, including the possibility of an increase in breast cancer among users, a link to osteoporosis, and a risk of low birth rate for infants exposed in utero. The USFDA is following its usual protocol with Depo-Provera and is continuing to monitor any adverse health effects. In the meantime, the consumer groups are pressing for universal use of informed-consent forms which follow a minimum standard. Such a form is used by the NWHN and is reproduced as a companion to this article.